A bispecific HER2/CD3 targeting FynomAb with excellent tumor killing and favorable pharmacokinetic properties

被引：0
|
作者：
Wuellner, Ulrich [1 ]
Buller, Fabian [1 ]
Klupsch, Kristina [1 ]
Brack, Simon [1 ]
Zbinden, Irene [1 ]
Santimaria, Roger [1 ]
Attinger-Toller, Isabella [1 ]
Koenig-Friedrich, Susann [1 ]
Bertschinger, Julian [1 ]
Grabulovski, Dragan [1 ]
机构：
[1] Covagen AG, Zurich, Switzerland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-656
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
656
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity
    Wuellner, Ulrich
    Klupsch, Kristina
    Buller, Fabian
    Attinger-Toller, Isabella
    Santimaria, Roger
    Zbinden, Irene
    Henne, Patricia
    Grabulovski, Dragan
    Bertschinger, Julian
    Brack, Simon
    ANTIBODIES, 2015, 4 (04) : 426 - 440
  • [2] Fynomer-antibody fusions targeting HER2 and CD3 for selective killing of HER2 overexpressing tumor cells.
    Woods, Richard
    Brack, Simon
    Klupsch, Kristina
    Wuellner, Ulrich
    Buller, Fabian
    Santimaria, Roger
    Attinger-Toller, Isabella
    Koenig-Friedrich, Susann
    Zbinden, Irene
    Bertschinger-Ehrler, Julian
    Grabulovski, Dragon
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A bispecific HER2 targeting FynomAb with superior anti-tumor activity and novel mode of action
    Schade, Babette
    Brack, Simon
    Attinger-Toller, Isabella
    Klupsch, Kristina
    Woods, Richard
    Hachemi, Helen
    von der Bey, Ulrike
    Kooenig-Friedrich, Susann
    Bertschinger, Julian
    Grabulovski, Dragan
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors
    Cugnetti, Ana Paula
    Liu, Haizhen
    McNeeley, Patricia
    Wheeler, Christina
    Lucas, Matthew
    Xing, Charles
    Joyner, Solmarie
    Johnson, Kyrie
    Woodard, Kathryn
    Zhou, Wei
    Chang, Cathy
    Frey, Gerhard
    Boyle, William J.
    Short, Jay M.
    CANCER RESEARCH, 2023, 83 (07)
  • [5] Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
    Lopez-Albaitero, Andres
    Xu, Hong
    Guo, Hongfen
    Wang, Linlin
    Wu, Zhihao
    Tran, Hoa
    Chandarlapaty, Sarat
    Scaltriti, Maurizio
    Janjigian, Yelena
    de Stanchina, Elisa
    Cheung, Nai-Kong V.
    ONCOIMMUNOLOGY, 2017, 6 (03):
  • [6] GBR1302-BEAT® bispecific antibody targeting CD3 and HER2 demonstrates a higher anti-tumor potential than current HER2-targeting therapies
    Back, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
    Slaga, Dionysos
    Ellerman, Diego
    Lombana, T. Noelle
    Vij, Rajesh
    Li, Ji
    Hristopoulos, Maria
    Clark, Robyn
    Johnston, Jennifer
    Shelton, Amy
    Mai, Elaine
    Gadkar, Kapil
    Lo, Amy A.
    Koerber, James T.
    Totpal, Klara
    Prell, Rodney
    Lee, Genee
    Spiess, Christoph
    Junttila, Teemu T.
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (463)
  • [8] A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
    Yu, Shengnan
    Zhang, Jing
    Yan, Yongxiang
    Yao, Xudong
    Fang, Lijuan
    Xiong, Hui
    Liu, Yang
    Chu, Qian
    Zhou, Pengfei
    Wu, Kongming
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)
  • [9] A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
    Shengnan Yu
    Jing Zhang
    Yongxiang Yan
    Xudong Yao
    Lijuan Fang
    Hui Xiong
    Yang Liu
    Qian Chu
    Pengfei Zhou
    Kongming Wu
    Journal of Experimental & Clinical Cancer Research, 38
  • [10] Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition
    Chang-ling Gu
    Hai-xia Zhu
    Lan Deng
    Xiao-qing Meng
    Kai Li
    Wei Xu
    Le Zhao
    Yue-qin Liu
    Zhen-ping Zhu
    Hao-min Huang
    Acta Pharmacologica Sinica, 2022, 43 : 672 - 680
12345